CuraVac team is composed of 3 key people in the center of collaborative network of the highest quality from the industry and the academic world.
He is responsible for the daily management of the company.
Dr. Huberty has over 25 years experience as a successful entrepreneur and manager. He also founded and is CEO of IDEAS in Belgium, a company specializing in CAD/CAM production of customized orthopaedic and normal footwear for which he was awarded the Young Entrepreneur of the Year award in 1993.
He is a medical doctor and graduate of the Catholic University of Louvain (UCL), Belgium. During his medical studies, he specialized in the use of computers in medicine and worked as a research fellow at UCLA. He has studied the research of Professor Blalock for personal reasons, as a sufferer from Myasthenia Gravis.
At CuraVac, he is responsible for the scientific research and discoveries as well as any laboratory proceedings related to this technology. It is also his role to guarantee the scientific feasibility of the product. He has been a professor of Microbiology since 1984.
He joined the University of Alabama at Birmingham (UAB) faculty in 1986 as Professor of Physiology and Biophysics and in 2009 became Professor of Medicine. He has been adjunct Professor at Auburn University and Utrecht University (NL). His areas of research centre on rational drug and vaccine design.
Professor Blalock is a renowned scientist with more than 300 scientific publications in top ranked peer reviewed scientific journals and whose work has been funded all through out his career.
Amongst his most notable discoveries is “The immune system as a sixth sense”. A discovery for which he has gained the respect of the scientific community and for which he was invited to open the Nobel Symposium in 2004.
Professor Blalock received his B.S. and Ph.D. degrees in 1971 and 1976, respectively, from the University of Florida. After one year postdoctoral training at the University of Texas Medical Branch, Galveston, he joined the faculty in 1977, and earned the title of Professor of Microbiology in 1984.
After a training period at SmithKline Beecham Biologicals (now GSK Vaccines), Nicolas participated to the development of the biologics Contract Manufacturing Organisation Henogen (later acquired by Novasep). Under his leadership as Process Development Director and later as Business Development Director, the company grew from 20 to 120 people and the revenues exceeded 12M EUR.
He then created in 2006 his consulting and management company and joined the Artelis funding team to develop the business of disposable cell culture bioreactors. After a grow phase from 6 to 40 people, Artelis was acquired by ATMI LifeSciences and, from this date, Nicolas took care of the Asian business, developing the bioreactor sales from scratch in several countries.
In 2009, he also joined the European Vaccine Initiative as Production Director, in charge of subcontracting the vaccines clinical batches.
He co-founded Bioxodes in 2010, a company developing innovative biotech drugs from the tick saliva where he is in charge of the manufacturing activities.
In 2007, he joined CuraVac as Chief Operating Officer in charge of managing the network of subcontractors (CROs and CMOs). He is scientific coordinator of the Myasterix consortium.
Working as a part-time consultant, Mike Yates is supporting the development of launch strategy.
Mike began his career in local commercial operations, working for SmithKline Beecham, Eli Lilly and Co. and Sanofi Aventis in both the UK and Romania. During this time, he successfully led several brand re-launches, health technology assessment submissions and organizational restructures to optimize franchise performance.
Over the last 4 years, he has worked in the global epilepsy franchise for UCB Pharma. In his last role, he was the global commercial lead for a pre-launch epilepsy brand and was accountable for leading the cross-functional team accountable for launch strategy and life cycle planning.
Mike has a deep appreciation for strategic market access challenges and the need to fully integrate the commercial, clinical and technical perspectives early in order to deliver compelling differentiation throughout the asset’s life cycle.